title: [Ischemia-reperfusion injury after lung transplantation].
abstract: Lung ischemia-reperfusion is characterized by diffuse alveolar damage arising from the first hours after transplantation. The first etiology of the primary graft dysfunction in lung is ischemia-reperfusion. It is burdened by an important morbi-mortality. Lung ischemia-reperfusion increases the oxidative stress, inactivates the sodium pump, increases the intracellular calcium, leads to cellular death and the liberation of pro-inflammatory mediators. Researches relative to the reduction of the lung ischemia-reperfusion injuries are numerous but few of them found a place in common clinical practice, because of an insufficient level of proofs. Ex vivolung evaluation is a suitable technique in order to evaluate therapeutics supposed to limit lung ischemia-reperfusion injuries.
authors.affiliation: CHU de Grenoble, pôle urgences et médecine aiguë, CS 10217, 38043 Grenoble cedex 09, France; Laboratoire TIMC-IMAG, UMR 5525, domaine de la Merci, 38706 La Tronche cedex, France. Electronic address: sfgennai@gmail.com.
authors.forename: Stéphane
authors.initials: S
authors.lastname: Gennai
authors.affiliation: Université Joseph-Fourier, laboratoire de bioénergétique fondamentale et appliquée, Inserm U1055, BP 53, 38041 Grenoble cedex 09, France.
authors.forename: Christophe
authors.initials: C
authors.lastname: Pison
authors.affiliation: CHU de Grenoble, pôle urgences et médecine aiguë, CS 10217, 38043 Grenoble cedex 09, France; Laboratoire TIMC-IMAG, UMR 5525, domaine de la Merci, 38706 La Tronche cedex, France.
authors.forename: Raphaël
authors.initials: R
authors.lastname: Briot
mesh_terms: D000255:Adenosine Triphosphate / Q000378:metabolism; D017209:Apoptosis; D001993:Bronchodilator Agents / Q000627:therapeutic use; D002118:Calcium / Q000378:metabolism; D002248:Carbon Monoxide / Q000627:therapeutic use; D016207:Cytokines / Q000378:metabolism; D006801:Humans; D057775:Ischemic Postconditioning; D019194:Ischemic Preconditioning; D016040:Lung Transplantation / Q000009:adverse effects*; D033681:Mitochondrial Membrane Transport Proteins / Q000378:metabolism; D019255:NADPH Oxidases / Q000378:metabolism; D009569:Nitric Oxide / Q000378:metabolism / Q000627:therapeutic use; D009926:Organ Preservation; D018384:Oxidative Stress / Q000502:physiology; D010100:Oxygen / Q000008:administration & dosage; D011650:Pulmonary Alveoli / Q000098:blood supply; D011663:Pulmonary Surfactants / Q000627:therapeutic use; D017382:Reactive Oxygen Species / Q000378:metabolism; D015424:Reperfusion / Q000379:methods; D015427:Reperfusion Injury / Q000209:etiology* / Q000503:physiopathology / Q000517:prevention & control; D012121:Respiration, Artificial / Q000379:methods; D012720:Severity of Illness Index; D000254:Sodium-Potassium-Exchanging ATPase / Q000378:metabolism
chemical_list: D001993:Bronchodilator Agents; D016207:Cytokines; D033681:Mitochondrial Membrane Transport Proteins; D011663:Pulmonary Surfactants; D017382:Reactive Oxygen Species; D009569:Nitric Oxide; D002248:Carbon Monoxide; D000255:Adenosine Triphosphate; D019255:NADPH Oxidases; D000254:Sodium-Potassium-Exchanging ATPase; D010100:Oxygen; D002118:Calcium